美股A股
StockGist
Back
8-K2026-03-30· grok-4-1-fast-non-reasoning

ASMB · Assembly Biosciences, Inc.

0001193125-26-131872

SEC filing

Summary

Assembly Biosciences approved the 2026 Corporate Bonus Plan and increased CEO Jason A. Okazaki's bonus target from 60% to 65% of base salary, effective for fiscal year 2026.

Key takeaways

Full analysis

The approval of the 2026 Corporate Bonus Plan establishes a structured incentive framework tying employee compensation to corporate performance metrics approved by the Board and individual goals, with varying weights by role—100% corporate for the CEO, down to 25% for associate directors and below. This aligns executive pay directly with company-wide financial and operational achievements, potentially driving focus on key milestones. The specific increase in CEO Jason A. Okazaki's target bonus to 65% of base salary reflects committee confidence in his leadership amid the new plan's rollout, with actual payouts determined post-performance period review and capped at 1.5x target if employed through payment.